Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

BOEHRINGER MANNHEIM PHARMACEUTICALS HEAD IS EX-BEECHAM PRESIDENT Ted Wood, Boehringer Mannheim America Chairman Robert Schwindt announced Dec. 20. Wood will assume the title of president of Boehringer Mannheim Pharmaceuticals Corporation (BMPC) on Jan. 13. He succeeds Rainer Hoffmann, who resigned in May. Wood, 53, spent 15 years at Beecham Labs and was its president at the time of the 1989 merger with SmithKline. After the merger, Wood was named exec VP-sales and marketing of the combined company but left in April 1990. Before joining Beecham, Wood spent 10 years with the pharmaceutical division of Dow Chemical. Commenting on the appointment, Schwindt said: "Ted Wood is particularly well qualified to lead BMPC in this period of rapid growth. During his career with Beecham he had a broad range of responsibilities and leadership experience including regulatory affairs, product development, manufacturing, finance and human resources." Wood said he was impressed by the firm's commitment to establishing a U.S. presence, calling the task an "exciting challenge." He added that the company has "a good track record" in the diagnostics and orthopedic areas. Finally, he cited an "interesting expertise in biotechnology" which he feels gave the company an early lead in "biologically obtained pharmaceuticals." Wood will join a management team at BMPC that includes ex-FDA Bureau of Drugs Director Richard Crout, who serves as VP and medical director. The Rockville, Md.-based U.S. pharmaceutical arm of the German firm Boehringer Mannheim International, BMPC is a subsidiary of Boehringer Mannheim America, which also holds the diagnostics and biochemical firm Boehringer Mannheim Corp. and the orthopedics manufacturer DePuy. Boehringer Mannheim and SmithKline Beecham have a partnership agreement for four cardiovascular drugs, including the beta blocker Kredex (carvedilol), which has a pending NDA. Two thromboxane receptor antagonists, sulotroban and daltroban, are in Phase III and Phase I trials, respectively. SmithKline acquired rights to the compounds in December 1986. BMPC also has a modified plasminogen activator, ecoplase, in clinicals.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts